CAMP4 Trial Approved in Australia & Argentina, Connect for news, Ada & Ford Fund a grant, #S10e213

Friday, August 7, 2026 - Week 32   CAMP4 - Gaining momentum - Approval for trials in Australia & +$50M of cash from investors:https://investors.camp4tx.com/news-releases/news-release-details/camp4-therapeutics-secures-australian-regulatory-clearance - Profile on CNBC Cures: https://www.cnbc.com/2026/08/06/camp4-advances-rare-disease-treatment-for-syngap1-into-human-trials.html Where they mentioned approval in Argentina!   $CAMP closed at $4.53 yesterday. https://www.google.com/finance/beta/quote/CAMP:NASDAQ   MAKE SURE YOU ARE REGISTERED WITH CONNECT https://curesyngap1.org/curesyngap1connect/   USA 🇺🇲: Use your ICD-10, F78.A1   CITIZEN Sign up now! https://www.citizen.health/ai-advocate/syngap1   SOCIAL MATTERS 5,156 LinkedIn.  https://www.linkedin.com/company/curesyngap1 1.6k YouTube.  https://www.youtube.com/@CureSYNGAP1 11.1k Twitter https://twitter.com/cureSYNGAP1 43.7k Insta https://www.instagram.com/curesyngap1   Like and subscribe to this podcast wherever you listen. https://curesyngap1.org/podcasts/syngap10 Episode 213 of #Syngap10 #SYNGAP1 #CureSYNGAP1 #Podcast #PatientAdvocacy